Moreover, adjusting for hs-CRP and IL-6 almost eliminated the associations of LBP with metabolic syndrome and most of its traits (Table 2, model 3), whereas controlling for HMW-adiponectin and leptin had little impact on the associations.
Moreover, adjusting for possible confounders pioglitazone (OR = 0.68, P > 0.05) or rosiglitazone (OR = 0.74, P > 0.05) had no significant trend toward decreasing gastric cancer risk with increasing cumulative doses ≥ 1 year, respectively.
Moreover, we adjusted for baseline differences where possible.
Moreover, we adjusted for time dependent measures of fasting glucose and oral glucose tolerance.
Moreover, when adjusted for confounding covariates, neither age nor sex was associated with renal events.
Moreover, we adjusted for a number of confounding factors and thereby minimized confounding.
Moreover, when adjusted for natal litter size, more variation was removed from birth mass than from birth head width.
Moreover, we adjusted for any previous admission for CHF, COPD, MI, or diabetes and number of days spent in intensive and coronary care units.
Moreover, we adjusted for age, race, sex, and SES, as well as for any prior cardiopulmonary admission and severity of disease.
